-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer patients who have the option of a mastectomy (NSM) or skin-retaining mastectomy (SSM) immediately after a new assisted chemotherapy (NACT) have a breast reconstruction (IBR), and researchers recently compared the effects of the breast cancer procedure on patients' long-term oncology results compared to traditional total mastectomy (CM).
case-control study, which was conducted with a retrospective, tendentive score match, was conducted at Asan Medical Center in Seoul, South Korea.
between January 1, 2010 and November 30, 2016, a total of 1,266 breast cancer patients under the ACT under performed a mastectomy, with or without breast reconstruction.
323 patients who received IBR and NSM/SSM and 323 patients who simply received CM were selected for long-term tumor prognosis after the tendency score match.
the main endpoints of the study were 5 years of local recurrence, disease-free survival, no distant transfer survival and total survival.
follow-up period was 67 months in the IBR group and 68 months in the CM group alone.
age of patients in the IBR group was 42 years, and the average age of patients in the CM group alone was 46.
IBR and CM groups did not observe significant differences in local recurrence rates (3.7% vs 3.4%), regional recurrence rates (7.1% vs 5.3%) or distant transfer rates (17.3% vs 18.6%).
IBR and CM groups, there was no local re-occurrence rate for 5 years (95.6% vs. 96.7%; HR: 1.124), disease-free survival rate (76.5% vs 79.9%; HR: 1.9%) 089), there was no significant difference in distance transfer survival rate (82.5% vs. 82.5%; HR: 0.941) or total survival rate (92.0% vs 89.3%; HR: 0.847).
, for breast cancer patients, the long-term oncology results of breast reconstruction patients after breast augmentation surgery were comparable to total mastectomy after new complementary chemotherapy.
.